Celltrion Healthcare commits to develop lab tests for evidence-based decision-making in anti-TNF treatment

News follows recent FDA approval of InflectraTM (biosimilar infliximab, other brand name Remsima®), now the first and only biosimilar monoclonal antibody (mAb) approved in the US

Celltrion Healthcare, a global biopharmaceutical company, today announced its research commitment to develop laboratory tests that will determine both drug and anti-drug antibody (ADA) levels in the blood, enabling physicians to identify when patients on an anti-tumour necrosis factor (anti-TNF) drug require a change of dose or a switch to a different treatment in the class.

Mr. Man Hoon Kim, President, Celltrion Healthcare said:

Biologics and biosimilars tested with advanced analytical methods to assess drug and ADA levels could be used for developing tailored treatments. Celltrion is fully committed to support this type of research to develop affordable laboratory tests, or kits, for routine monitoring that allows personalized infliximab treatment according to the disease status of individual patients.

A group of researchers released an observational study in rheumatoid arthritis (RA), the results of which were presented at the recent European League Against Rheumatism annual congress (EULAR 2016). The study assessed the correlation between ADA levels in patients with RA and circulating blood levels of an anti-TNF therapy as a potential predictor of a patient’s response to treatment. The results showed that high levels of ADAs at the beginning of treatment were associated with a poor response at a later stage.

Discussing the results, study investigator Professor Chamaida Plasencia of La Paz University Hospital-Idipaz in Madrid, Spain, said:

Therapeutic drug monitoring is important in patients with chronic inflammatory diseases using biological therapies such as TNF inhibitors. The serum trough levels of TNF inhibitors are closely correlated with clinical efficacy. Several factors are associated with a faster drug clearance including anti-drug antibody formation. Differences in the structure of TNF inhibitors are crucial in terms of drug immunogenicity. Recent evidence demonstrates that drug and/or anti-drug antibody level monitoring at early stages of therapy is correlated with clinical outcomes. Therapeutic drug monitoring could help physicians make evidence-based decisions about treatment, thus avoiding the undesirable consequences of immunogenicity such as treatment failure.

Celltrion’s ongoing commitment to evidence-based healthcare was also demonstrated by the company’s decision to undertake extension studies of its registration trials up to 102-week: PLANETRA and PLANETAS. Published in Annals of the Rheumatic Diseases in April 2016, the extension studies showed that Remsima® was well-tolerated and effective over two years, and that the efficacy, safety and immunogenicity of Remsima® and the reference medicinal product (RMP) were comparable both in patients who remained on Remsima® and in those who were switched from the RMP.

Mr. Kim added:

Remsima was diversely tested up to 102-weeks for immunogenicity; 3mg/kg and 5mg/kg, RA patients and AS patients, combination therapy and monotherapy, Remicade oriented ADA and Remsima oriented ADA, switch group and maintenance group. All data consistently support the comparability claim and, once published, would provide additional scientific grounds for research similar to Professor Chamaida Plasencia’s.

In addition, the US Food and Drug Administration (FDA) approved Celltrion’s biosimilar infliximab in April this year for the treatment of serious autoimmune diseases, including RA and IBD. It is now the first and only biosimilar mAb therapy, and only the second biosimilar, to be approved in the US. Pfizer will assume exclusive marketing authority in the US under the brand name InflectraTM and will work closely with Celltrion Healthcare to prepare for the launch.

Mr. Kim said:

We fully support the stringent regulatory pathways in place for biosimilars in Europe and the US. We are proud that our comprehensive data package for Remsima® met these high standards and firmly believe they should be maintained for all future biosimilars – whether for infliximab or another anti-TNF medicine.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
You might also like...
Autistic adults have worse health and poorer quality healthcare